Browse the corpus

Erlotinib is a tyrosine kinase receptor inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer and advanced pancreatic cancer. This drug inhibits the epidermal growth factor receptor (EGFR), affecting both wild-type and mutated EGFRs, which are crucial in cellular differentiation, proliferation, and angiogenesis. Erlotinib’s efficacy is influenced by proper patient selection based on thorough diagnostic evaluation. The drug has a narrow therapeutic index, and its use is associated with adverse effects such as diarrhea and rash. Proper patient selection based on a thorough diagnostic workup is essential to achieve superior outcomes compared to traditional chemotherapy. This activity provides an overview of erlotinib’s pharmacological features, including its indications, mechanism of action, contraindications, adverse event profile, dosing, and relevant drug interactions. This activity emphasizes interprofessional collaboration among healthcare providers to optimize dosing, manage adverse effects, and ensure safe and effective treatment outcomes through multidisciplinary efforts in monitoring, patient counseling, and overall therapeutic management. In addition, this activity provides clinicians with the knowledge to optimize patient selection through thorough diagnostic evaluation, improving therapeutic outcomes while offering insights into erlotinib’s safety profile, narrow therapeutic index, and potential adverse effects, thereby enhancing overall treatment efficacy. Objectives: Identify the indications and contraindications for erlotinib therapy in patients with non-small cell lung cancer and advanced pancreatic cancer. Implement evidence-based dosing strategies for erlotinib, considering patient-specific factors such as smoking status and hepatic impairment. Select appropriate interventions to manage common adverse effects of erlotinib, such as diarrhea and rash, to improve patient quality of life. Collaborate with a multidisciplinary healthcare team, including oncologists and pharmacists, to provide comprehensive care for patients receiving erlotinib therapy. Access free multiple choice questions on this topic.

According to the manufacturer, cancer patients can tolerate weekly doses of up to 1600 mg before toxicity occurs. If an overdose of erlotinib is suspected, symptomatic treatment and discontinuation of the medication are recommended. Therapy should be withheld if the patient experiences persistent severe diarrhea unresponsive to medical management (eg, loperamide), severe rash unresponsive to treatment, or keratitis of grade 3 or 4 (NCI-CTC version 4.0), or grade 2 keratitis lasting longer than 2 weeks. Erlotinib tablets should be discontinued if a patient experiences any of the following adverse events: Interstitial lung disease Severe hepatic toxicity that does not improve significantly or resolve within 3 weeks Gastrointestinal perforation Corneal perforation or severe ulceration [18]

Effective communication among healthcare team members is essential for the successful administration of erlotinib, which has a narrow therapeutic index and is typically prescribed by oncology specialists. Clinicians must handle the drug with care, as it is classified as a hazardous agent by the National Institute for Occupational Safety and Health (NIOSH). All healthcare team members, including primary care providers, nursing staff, and pharmacists, should be aware of the risks of diarrhea, rash, and severe adverse events. Clinicians should be aware of the CYP enzyme interactions that can affect blood levels of erlotinib, either elevating or decreasing them. Consequently, it is essential to frequently monitor patients' medication lists to prevent these interactions. This is where the expertise of a board-certified oncology pharmacist is invaluable, as they collaborate with the prescriber on optimal dosing, assess potential interactions, and provide counseling to patients about adverse events. Nursing staff should also be aware of these adverse effects during their monitoring, as they typically have more patient contact than other healthcare team members. The entire healthcare team must guide the patient on the correct administration of the medication, which should occur either before or 2 hours after meals. Additionally, the primary care team should be informed of the recommendation that women taking this medication should avoid becoming pregnant, and discussions about ongoing contraception should be encouraged. These strategies and interprofessional actions contribute to optimizing therapeutic outcomes and enhancing patient safety with erlotinib.